Genentech's Kadcyla meets in Phase III as breast cancer adjuvant

Genentech Inc. said adjuvant treatment with Kadcyla ado-trastuzumab emtansine met the primary endpoint of improving invasive disease-free survival (DFS) vs. Herceptin trastuzumab in the Phase III KATHERINE trial to treat breast cancer. The open-label, international trial enrolled 1,487 patients with HER2-positive early breast cancer who did not achieve a pathological complete response and have residual disease in the breast and/or axillary lymph nodes following neoadjuvant treatment.

Genentech said it will submit the data to global health authorities, including FDA and EMA. Full data from KATHERINE will be presented at the San Antonio Breast Cancer Symposium in December...